Nektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb
September 27, 2016 7:45 AM EDTSAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at 9:00 a.m. Eastern Time (ET)/6:00 a.m. Pacific Time (PT) on Tuesday, September 27, 2016. A live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website at... More
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214
September 27, 2016 6:59 AM EDTNew collaboration will explore the potential benefits of combining Bristol-Myers Squibbs anti-PD-1 antibody with Nektars CD122-biased agonist in five tumor types
SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY)... More
